Prof. Dr. med. Monika Brüggemann
                Facts
                            Phone:
                            +49-431-500-24980
                        
                                        
                                            
                            E-Mail:
                            m.brueggemann@med2.uni-kiel.de
                        
                                        
                                            
                            Website:
                            
                            
                                
                            
                        
                                        
                                            
                            Affiliations:
                            Clinic for Internal Medicine II, Hematology and Oncology / University Medical Center Schleswig-Holstein, Campus Kiel, Divison of Hematological Special Diagnostics / University Medical Center Schleswig-Holstein, Campus Kiel
                        
                                        
                                            
                            Address:
                            Langer Segen 8-10, 24105 Kiel
                        
                                        
                                        
                                        
                                    Curriculum vitae
Education/Training
| Since 2015 | Head of Division of Specialized Hematology Diagnostics in the Department of Hematology, University Hospital Kiel | 
| 2011-2015 | Senior Physician, Department of Hematology, University Hospital Kiel | 
| 2010 | Board Certification as a Specialist in Laboratory Medicine | 
| 1999-2011 | Residency/Fellowship (Departments of Hematology, Laboratory Medicine, Immunology, Infection Medicine) University Hospital Kiel | 
| 1997-1998 | Internship/Residency, Department of Hematology, University Hospital Essen | 
| 1995-1996 | Internship/Residency, Department of Hematology and Oncology, Community Hospital, Duisburg | 
| 1988-1995 | Medical School in Essen | 
Research Experience/Academic Appointments
| 2007 | Postdoctoral lecture qualification in Molecular Hematology | 
| Since 1998 | Clinical lecturer and Research Fellow, Department of Hematology, University Hospital Kiel | 
| 1996-1997 | PostDoc, Molecular Genetic Laboratory, Department of Hematology, University of Göttingen, Germany | 
| 1993-1996 | Doctorate thesis, Department of Pediatrics, University Hospital Essen (Prof. Dr. U. Stephan) | 
| Fields of Interest | Translational research related to molecular genetics and MRD diagnostics of lymphoproliferative diseases. | 
Important Scientific Prizes/Functions
| Since 2019 | Member of the Steering Committee of the Clinician-scientist Academy Kiel | 
| Since 2019 | Chair of the Laboratory Working Group of the DGHO | 
| Since 2019 | Member of the Doctorate Board of the Medical Faculty of the University Kiel | 
| Since 2016 | Member of the Gender Equality Board of the Medical Faculty of the University Kiel | 
| Since 2016 | Member of the Protocol Committee of the BFM-Study Group and of the FLOW-BFM Network | 
| Since 2016 | Board member of the EuroFlow Consortium | 
| Since 2015 | Board member of the European ESG/EuroMRD Consortium | 
| Since 2012 | Scientific secretary and member of the Protocol Committee of the German Multicenter ALL Study Group (GMALL) | 
| 2011 | Fritz Acker Memorial Award for clinical research in hemato-oncology | 
| Since 2006 | Member of the European EuroFlow Consortium | 
| Since 2003 | Member of the European ESG/EuroMRD Consortium | 
| Since 1999 | Coordinator of the MRD analyses within the German Multicenter ALL Study Group | 
| Since 1998 | Member of the European BIOMED-2/EuroClonality Consortium | 
Project-related publications
				P1, P3, P4, Z			
				
		NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation
				P2, P1, P3, INF			
				
		Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
				P1, P3, P6, P7, Z			
				
		The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis
				P1, P3, P4, INF, Z			
				
		The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age
				P1, P3, P4, Z, INF			
				
		Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
				P1, P3, P4, INF			
				
		Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications
				P1, P3, P4, INF, Z			
				
		UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
				P3, P4, P6, P7, Z			
				
		Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
				P3, P6, P7, Z			
				
		Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia
				P1, P3, P4, INF, Z			
				
		IGH Rearrangement Evolution in Adult KMT2Arearranged B-cell Precursor ALL: Implications for Cell-of-origin and MRD Monitoring
				P3			
				
		Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies
				P1, P3, P6, Z			
				
		CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia
				P1, P3, P4, Z			
				
		Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia
				P1, P3, P4, Z